All News

2019

February

Media Release / Feb 13, 2019

Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease

Read More

January

Media Release / Jan 30, 2019

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

Read More
Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Read More
Media Release / Jan 07, 2019

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

Read More
2018

December

Media Release / Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Read More
Media Release / Dec 21, 2018

Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)

Read More
Media Release / Dec 20, 2018

Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies

Read More
Media Release / Dec 20, 2018

Novartis announces new CEO of Oncology Business Unit

Read More
Media Release / Dec 19, 2018

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

Read More
Media Release / Dec 19, 2018

Alcon Announces Acquisition of Tear Film Innovations, Inc.

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More